Introduction to Deep Transmagnetic Stimulation (dTMS)
Deep Transmagnetic Stimulation (dTMS) represents a cutting-edge advancement in the field of neuromodulation. Building upon the principles of Transcranial Magnetic Stimulation (TMS), dTMS targets deeper brain structures with precision, offering new hope for individuals with treatment-resistant mental health conditions.
How Does dTMS Differ From Traditional TMS?
While traditional TMS primarily targets surface areas of the brain, dTMS utilizes specialized coils and technology to reach deeper structures. By precisely targeting these areas, dTMS aims to modulate neural circuits implicated in various mental health disorders more effectively.
Conditions Treated With dTMS
dTMS is FDA-approved for the following disorders:
- Major Depressive Disorder (MDD)
- Obsessive-Compulsive Disorder (OCD)
- Anxious Depression
- Smoking-cessation
AND THE BRAINSWAY SYSTEM IS THE ONLY ONE WITH AN FDA INDICATION FOR TREATING DEPRESSION IN PEOPLE OVER 65 YO.
Treatment Process and Experience
- Sessions: Similar to traditional TMS, dTMS involves multiple sessions scheduled over several weeks. The protocols for each diagnosis are based on the FDA trials and range from 29-34 treatments, each lasting close to 19 min.
- Procedure: During a session, the patient sits comfortably while a specialized dTMS coil is positioned over the head. The treatment is non-invasive, and patients typically experience minimal discomfort.
- Safety and Side Effects: dTMS is considered safe, with side effects generally mild and transient. These may include headache, scalp discomfort, or mild irritation at the stimulation site.
Effectiveness and Benefits
Studies suggest that dTMS can offer significant benefits for individuals who have not responded adequately to other treatments. Benefits may include:
- Improved Mood: Reduction in depressive symptoms and enhanced overall emotional well-being.
- Enhanced Functioning: Better ability to engage in daily activities and social interactions.
- Long-term Relief: sustained improvement in symptoms over time.
References:
- National Institute of Mental Health (NIMH)
- U.S. Food and Drug Administration (FDA)
- Clinical studies and research in neuromodulation